Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-196 safety, tolerability, and NSAID-induced small bowel injury study in healthy volunteers
NL-OMON51579Active, not recruiting
- Sponsor
- Kallyope
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of K-196 in inflammatory bowel disease (IBD) (3 arms), sponsored by Kallyope. Primary endpoint: Safety and tolerability of multiple oral doses of K-196 alone and in combination with naproxen/omeprazole. Started May 2023; status: active, not recruiting.
02
Drugs
K-196
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON51579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51579.